https://ift.tt/os9kIx3 Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a prima...
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
https://ift.tt/mFePvaq from Sanofi - Aventis Groupe https://ift.tt/3Npy0tz via IFTTT " May good health envelop you, spurring a q...
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
https://ift.tt/eY2VpqD from Sanofi - Aventis Groupe https://ift.tt/qUx9Cjr via IFTTT " May good health envelop you, spurring a quic...
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
https://ift.tt/WhUJOou from Sanofi - Aventis Groupe https://ift.tt/eKjVlJE via IFTTT " May good health envelop you, spurring a quic...
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
https://ift.tt/RnGcMUB Sarclisa ® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagn...
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
https://ift.tt/4xvnado R&D Day from Sanofi - Aventis Groupe https://ift.tt/3KMTzsa via IFTTT " May good health envelop you, sp...
Press Release: Sanofi’s Consumer Healthcare unit launches the Shared Care Collective, an advisory group working to advance sustainability
https://ift.tt/Fv1VqcX Sanofi’s Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainab...
Subscribe to:
Posts
(
Atom
)